AUA. E. Uranov

A. E. Uranov

*This is an algorithmically generated author record based on publicly available information.

A. E. Uranov has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimizing compliance with clinical guidelines using a clinical decision support system in patients with hypertension and atrial fibrillation in real-world practice: a cluster-randomized comparative study INTELLECT-2

    by D. V. Duplyakov, D. A. Shebonkina, A. E. Uranov, I. L. Mikheenko, K. S. Astrakova, A. A. Gartung, E. V. Adonina, A. A. Tukhbatova, В. П. Кузьмин, G. A. Fedorova, et al.

    Aim . To evaluate the impact of a clinical decision support system (CDSS) in the management of patients with hypertension (HTN) and atrial fibrillation (AF) on compliance with clinical guidelines in real-world clinical practice. Material and methods. A cluster-randomized comparative study was conducted in 8 internal medicine departments in Samara. The departments were randomized into two following groups: one with the CDSS for prescribing anticoagulant, antiarrhythmic, and antihypertensive therapy (n=3; 2 inpatient and 1 outpatient department) and one without the CDSS — routine clinical practice (n=5; 3 inpatient and 2 outpatient departments). The study included patients with both hypertension and AF. The mean follow-up period was 11,5±5,7 months. R e sults . The study included 272 patients. Prescription rate of reduced doses of direct oral anticoagulants was significantly lower in the CDSS group as follows: apixaban 2,5 mg (0,8% vs 4,4%, pConclusion . CDSS implementation demonstrated a significant improvement in physician compliance with clinical guidelines in terms of prescribing optimal anticoagulant and antiarrhythmic therapy. Patients were more frequently referred for catheter ablation of AF. CDSS is associated with a reduced incidence of CVEs in patients with hypertension and AF.


  • Open Access

    Impact of a clinical decision support system on adherence to clinical guidelines in the management of patients with heart failure (SPHERA-HF study)

    by S. N. Tereshchenko, I. V. Zhirov, A. M. Shangina, F. N. Paleev, S. A. Boytsov, A. E. Uranov, K. S. Astrakova, I. L. Mikheenko, A. A. Gartung, A. A. Spiridonov, et al.

    Aim . To assess the impact of a clinical decision support system (CDSS) aimed at increasing physician compliance with clinical guidelines on heart failure (HF) in real-world practice in order to improve the effectiveness of managing this category of patients and clinical outcomes in pilot Russian regions. Material and methods . As part of the retrospective multicenter study SPHERA-HF, data of electronic health records from 49 medical facilities in three Russia regions were analyzed. The study participants were divided into inpatient and outpatient cohorts. The main inclusion criterion was a history of HF diagnosis. The features of patient management in real-world practice were studied before and after the implementation of the CDSS. Results. The study included 66166 patients. After CDSS imple neprilysin inhibitors in patients with HF with reduced ejection fraction increased in the in-hospital cohort from 32,9% to 52,3% (pConclusion. The study results indicate a positive impact of CDSS introduction on managing patients with HF.


  • Open Access

    The impact of clinical decision support systems on adherence to clinical guidelines and achieving target levels of low-density lipoprotein cholesterol in patients at risk of developing cardiovascular events (SuccESS)

    by K. S. Astrakova (Benimetskaya), I. L. Mikheenko, A. E. Uranov, A. A. Gartung, E. A. Kovalev, A. A. Spiridonov, I. I. Shestova, I. L. Strokolskaya, M. A. Meshkova, L. I. Esev, et al.

    Aim. To assess the effectiveness of clinical decision support system (CDSS) implementation strategy in increasing the frequency of low-density lipoprotein cholesterol (LDL-С) monitoring in patients hospitalized for acute cardiovascular events (CVEs), in patients with coronary artery disease (CAD) or dyslipidemia.Material and methods. A non-interventional, retrospective, multicentre study assessing the impact of a CDSS with automatic electronic medical record (EMR) data processing on adherence to guidelines in patients at risk of cardiovascular diseases (SuccESS) was performed. The study included two cohorts of patients from healthcare facilities in three regions of Russia. The main cohort consisted of patients hospitalized for acute CVEs, with 12,227 patients included in the first follow-up period and 11,364 patients included in the second follow-up period. The additional cohort consisted of patients with stable CAD or dyslipidemia, with 54 469 patients included in the first follow-up period and 94,616 patients included in the second follow-up period. The study assessed follow-up findings in real-world clinical practice before and after the CDSS was implemented (first and second follow-up periods, respectively). The median duration of follow-up in the main cohort was >158 days in the first follow-up period and >227 days in the second follow-up period.Results. In the second follow-up period the proportion of patients with available data on LDL-C control in the EMR increased from 12.3% to 18.8% (here and further — relative change: +52.3%, pConclusion. The study findings demonstrate the positive impact of CDSS on several parameters that determine the quality and organization of medical care. The CDSS can be used to improve clinical and managerial decisions.


  • Personalized approach to treatment choice using a digital profile of patient with cardiovascular diseases: the features of clinical decision-making support service

    by A.M. Shangina, K.S. Benimetskaya, Yu.E. Efremova, A.E. Uranov, E.A. Kovalev, I.L. Mikheenko, D.V. Losik, S.A. Boytsov

    Digital transformation of healthcare systems including artificial intelligence (AI) technologies and clinical decision-making support systems (CDSS) became popular worldwide. There is a growing need for early diagnosis and treatment of cardiovascular diseases with personalized approach to these issues. We reviewed appropriate foreign and domestic digital solutions in clinical practice. CDSS is valuable for physicians to receive a digitalized cardiovascular status and “hints” about the patient’s risks, examination and treatment in accordance with clinical guidelines considering absolute and relative contraindications, as well as AI-predicted missing important parameters. The doctor is able to choose the most effective and safe drug considering clinical trials and network meta-analysis in CDSS functionality. CDSS analytical dashboards allow the attending physician and healthcare organizer to automate dispensary follow-up by selecting patients with unmet health targets and assess the quality of care. CDSS-based automatic assessment of indications for drugs according to clinical recommendations allows planning preferential drug provision. CDSS has a potential to improve physician adherence to clinical guidelines and facilitate selection of personalized therapy for patients with cardiovascular diseases.


  • Open Access

    Retrospective Analysis of Lipid-Lowering and Antiplatelet Therapy Regimen by Clinical Decision Support Service Based on Real-World Data from Electronic Medical Records “Intellect 3 Study”

    by K. S. Benimetskaya, S. I. Provatorov, M. V. Ezhov, Y. S. Krivosheev, A. D. Gavrilko, A. E. Uranov, I. L. Mikheenko, E. A. Kovalev, A. V. Ponomarenko, A. M. Shangina, et al.

    Aim To evaluate prescription of lipid-lowering and antithrombotic therapy in clinical practice and to compare differences in recommendations using the clinical decision support service (CDSS). Material and methods Electronic medical records (EMR) of 300 patients from the Chazov National Medical Research Center of Cardiology, as well as from medical organizations controlled by the Department of Health of the Lipetsk Region and the Ministry of Health of the Voronezh Region, were analyzed for the period of August - December 2022, during the pilot implementation of CDSS. Retrospective information about the prescription of lipid-lowering and antithrombotic therapy from the EMR was compared with the CDSS guidelines under the expert supervision based on digitized clinical and laboratory profiles of patients. The study primary endpoint was a change in the initially prescribed lipid-lowering and / or antithrombotic therapy as per CDSS guidelines. Results Overall 292 patients were included in the final analysis; 46 (15.7 %) were from the primary prevention group and 246 (84.3 %) from the secondary prevention group. In group 1, the lipid-lowering therapy recommended by the CDSS differed by 50 % (pConclusion The use of CDSS may improve the practice of choosing lipid-lowering and antithrombotic therapy for prevention of cardiovascular complications.


  • Open Access

    Treatment of patients with chronic thromboembolic pulmonary hypertension

    by O. Ya. Vasiltseva, A. E. Uranov, A. G. Edemskiy, E. N. Kliver, D. S. Grankin, D. A. Sirota, A. B. Romanov, A. M. Chernyavskiy, О. Я. Васильцева

    The understanding of the tactics for managing patients with pulmonary hypertension (PH) of various etiologies is currently being developed. In August 2022, the European Society of Cardiology adopted new Guidelines for the management of patients with pulmonary hypertension. A separate cohort among them consists of patients with chronic thromboembolic pulmonary hypertension (CTEPH), classifi ed as Group 4 according to the WHO classifi cation. The possibilities of diagnosis, treatment methods, and their availability for this pathology have signifi cantly expanded over the past two decades. The aim of this study is to familiarize physicians with modern methods of treating CTEPH in order to timely refer patients to the most eff ective types of treatment currently available in expert centers in the Russian Federation. Materials and methods. The strategy for searching sources involved analyzing Medline (PubMed) and Scopus databases for the past 20 years using keywords such as diagnostic criteria for chronic thromboembolic pulmonary hypertension, treatment of chronic thromboembolic pulmonary hypertension. To search for additional materials on the topic, the lists of literature in relevant articles and reviews were analyzed.